eligibility_summary
Adults (≥18) with BCMA+ multiple myeloma after ≥2 prior lines, progressing/refractory, with measurable disease and ECOG 0–2, adequate marrow (Hb≥6, ANC≥600, Plt≥50k, lymph≥500, CD3≥150), renal (CrCl≥45), hepatic (ALT/AST≤3×ULN, TBIL/ALP≤2×, Alb≥3), cardiac (LVEF≥40%), and pulmonary (SpO2≥90%) function, contraception/consent required. Exclude recent therapies/HSCT, active infections (HBV/HCV/HIV/syphilis), major cardiac/neuro disease, pregnancy, live vaccines, severe drug allergy, recent surgery, poor venous access.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
NCT06691685 tests ESO‑T01, an intravenously administered, third‑generation self‑inactivating lentiviral gene therapy vector (drug: viral vector) that delivers a BCMA‑targeted chimeric antigen receptor to patients’ T cells in vivo (in‑vivo CAR‑T). Mechanism: the vector transduces autologous T cells to express an anti‑BCMA CAR, resultant CAR‑T cells recognize BCMA (TNFRSF17) on myeloma plasma cells and induce T‑cell activation, cytokine release, and cytotoxic lysis. Targets: autologous T cells (for gene transfer) and BCMA‑expressing multiple myeloma cells.